Health Condition 1: N768- Other specified inflammation of vagina and vulva
Conditions
Interventions
Intervention1: MetSheFlora – Vaginal Health (Slow-Release Capsule): Dosage form: Slow release Capsule
Route of Administration: Oral
Frequency: Twice a day
Mode of Usage- Take one slow-release capsule
Sponsors
Meteoric Biopharmaceuticals Pvt. Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1.The subject is a healthy non-pregnant/non-lactating females aged 18-55 years. 2.Presence of bacterial vaginosis (BV) as determined by gynaecological examination, including assessment for clinical symptoms such as abnormal vaginal discharge, malodour (moderate to very intense), and other relevant clinical indicators. 3.The subject is willing to provide written informed consent and follow study procedures. 4.The subject is willing to abide by the study protocol and restrictions, including abstaining from using any other intimate wash, lubricant, or treats during the study. 5.The subject is willing to use a highly effective method of contraception throughout the clinical investigation. This includes: a.Females of childbearing potential must practice and maintain an established method of birth control (e.g., IUD, hormonal implant device/injection, birth control pills, diaphragm, condoms with spermicide, partner vasectomy, or abstinence). b.Non-childbearing potential females who are surgically sterile, post-menopausal for at least 1 year, or have had a tubal ligation, must have been using hormonal contraception for at least 6 months and agree to continue using the same contraception for the study duration 6.Agreement for gynaecological pelvic examination by a Gynaecologist. 7.The subject is willing to abstain from sexual intercourse for a period of 24 hours before scheduled study visits to minimize potential interference with study assessments and measurements.
Exclusion criteria
Exclusion criteria: 1.The subject has used hormone replacement therapy in the last 3 months. 2.The subject has a history or visible evidence of chronic skin disease or regional infections, genital herpes, vaginal infections, or urinary tract infections. 3.The subject is pregnant/lactating, or are likely to become pregnant. 4.The subject has been diagnosed with or reported gynaecologic abnormalities within 60 days prior to study initiation that may influence study results. 5.The subject has severe systemic complications of viral infections, cardiovascular disorders, neurological disorders, renal disorders, or autoimmune disorders. 6.The subject has chronic infection/allergy/disease that may influence study results. 7.The subject has participated in clinical studies or received any investigational agent in the previous 30 days. 8.The subject has failed to satisfy the Investigator for fitness to participate for any other reason. 9.The subject has not experienced previous episodes of vaginal bleeding of unknown origin within the last 6 months of the screening visit. 10.The subject does not have vaginal prolapse and/or other medical conditions interfering with study conduct and participation. 11.The subject has not used systemic and/or local hormonal products for vaginal dryness or any other vaginal condition in the 3 months prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Evaluate the effect of the test treatment in term of change in the quality and odour of vaginal discharge. 2.Evaluate the effect of the test treatment in terms of changes in Nugent score. Timepoint: 1.Day 01 (before administration) for baseline, and post-dose on Day 15 and Day 30. 2. on Day 01 (before administration) for baseline, and post-dose on Day 30. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the effect of the test treatment in terms of change in vaginal pH.Timepoint: On Day 01 (before administration) for baseline, and post-dose on Day 15 and Day 30 evaluated by the Gynaecologist using pH paper.;Evaluate the effect of test treatment in terms change in VAS scoring for vaginal itching, and odour of vaginal discharge.Timepoint: On Day 01 (before application) for baseline, and post-dose on Day 15 and Day 30.;Evaluate the subject perception regarding the test treatment using a hedonic scale questionnaire for parameters such as smell, taste, overall palatability, perceived effectiveness of the test treatment.Timepoint: On Day 15 and Day 30 post dose.;Evaluate the safety of the test treatment by assessing various vulvar symptoms, including burning, stinging, moisture, flaking, epithelial mucosa, redness, dryness, odour, itching, and soreness, through clinical gynaecological examination.Timepoint: On Day 15 and Day 30 post dose.;Evaluate the safety of test treatment through the performance of safety laboratory tests including Complete Blood Count (CBC), Biochemical tests, and Urinalysis.Timepoint: Day 01 before dosing and Day 30 post-dose. | — |
Countries
India
Contacts
Public ContactMaheshvari Patel
NovoBliss Research Private Limited
Outcome results
None listed